Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Clin Rheumatol. 2011 Jul;30(7):1007-12. doi: 10.1007/s10067-011-1726-1. Epub 2011 Mar 24.
This study aims to report the therapeutic effects of anti-tumor necrotic factor antibody, infliximab, for treatment of neuro-Behcet's disease (NBD) and to review the literature. We described four patients (all male, median age 40 years old) who fulfilled the International Study Group criteria for Behcet's disease (BD) and presented with neurological complication. Demographic and clinical characteristics of the patients, dose, therapeutic effects, and adverse drug reaction (ADR) of infliximab were reported. Two patients had secondary progressive, one relapsing progressive, and one primary progressive course (median duration of BD and NBD 11 and 2 years, respectively). Two patients each received infliximab with 3 and 5 mg/kg infusions, respectively. The patients received infliximab for median of 22 weeks. Clinical responses were unsatisfactory for two patients on 3 mg/kg regimen; and good in two patients on 5 mg/kg and monthly intravenous 500-1,000 mg cyclophosphamide. Varicella zoster infection was seen as a major ADR in one patient. Our results with infliximab were not as promising as the previous reports. Infliximab, 5 mg/kg per dose with adjuvant immunosuppressive therapy, is probably more effective than other regimens.
本研究旨在报告抗肿瘤坏死因子抗体英夫利昔单抗治疗神经白塞病（NBD）的疗效，并复习文献。我们描述了 4 名符合白塞病国际研究组标准（BD）并出现神经并发症的男性患者（中位年龄 40 岁）。报告了患者的人口统计学和临床特征、英夫利昔单抗的剂量、疗效和药物不良反应（ADR）。2 例为继发性进行性，1 例为复发进行性，1 例为原发性进行性病程（BD 和 NBD 的中位病程分别为 11 年和 2 年）。2 例患者分别接受了 3 和 5mg/kg 的英夫利昔单抗治疗。患者接受英夫利昔单抗治疗的中位时间为 22 周。2 例患者在 3mg/kg 方案下的临床反应不佳，2 例患者在 5mg/kg 方案和每月静脉注射 500-1000mg 环磷酰胺的方案下反应良好。1 例患者出现水痘带状疱疹感染这一主要 ADR。我们使用英夫利昔单抗的结果不如之前的报道有希望。英夫利昔单抗，每次 5mg/kg 剂量联合辅助免疫抑制治疗，可能比其他方案更有效。
